

Mab 42: Claim 9(ii) - SEQ ID NO: 48, 55, 56 and 57**SEQ ID NO: 48: anti-CD3 light chain with CrossMab**

- CD3 VH Region (SEQ ID NO: 7; CDRs of SEQ NOs: 1, 2 and 3)
- CD3 CL Region

| EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKGLEWVSRIISKYNNYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCVRHGNFGNSYVSWFAYWGQGLTVTVSS|ASVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC|

SEQ ID NO: 52: heavy chain long arm with CrossMab and charge variant mutations

- BCMA VH (SEQ ID NO: 10; CDRs of SEQ NO: 21, 22 and 17)
- BCMA CH1 with Charge Variant Mutations
- CD3 VL (SEQ ID NO: 8; CDRs of SEQ NOs: 4, 5 and 6)
- CD3 CH1
- FC

| EVQLLESGGGLVQPGGSLRLSCAASGFTFSDNAMGWVRQAPGKGLEWVSAISGPGSSTYYADSVKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCAKVLGWFDYWGQGLTVTVSS|ASTKGPSVFPLAPSSKSTSGGTAALGCLV~~E~~DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVD~~E~~KVEPKSCD|GGGGSGGGGS|QAVVTQEPSTLSPGGTVTLTCSSTGAVTTSN~~Y~~ANVWQEKPGQAFRLIGGTNKRAPGTPARFSGSLLGGKAALTLGAQPEDEAEYCALWYSNLWVFGGGTKLTVLSS|ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKV|E PKSCDKHTHTCPPCPAPEAAGGPSVFLFPPKPKDRLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALGAPIEKTISKAKGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFFLYSKLTVDKSRWQQGNVFCFSVMHEALHNHYTQKSLSLSPGK|

SEQ ID NO 53: heavy chain short arm with charge variant mutations

- BCMA VH (SEQ ID NO 10s; CDRs of SEQ NOs: 21, 22 and 17)
- BCMA CH1 with Charge Variant Mutations
- FC

| EVQLLESGGGLVQPGGSLRLSCAASGFTFSDNAMGWVRQAPGKGLEWVSAISGPGSSTYYADSVKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCAKVLGWFDYWGQGLTVTVSS|ASTKGPSVFPLAPSSKSTSGGTAALGCLV~~E~~DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVD~~E~~KV|EPKSCDKHTHTCPPCPAPEAAGGPSVFLFPPKPKDRLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALGAPIEKTISKAKGQPREPQVCTLPPSRDELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFFLYSKLTVDKSRWQQGNVFCFSVMHEALHNHYTQKSLSLSPGK|

SEQ ID NO: 57: anti-BCMA light chain

- BCMA VL (SEQ ID NO: 14s; CDRs of SEQ NOs: 27, 28 and 20)
- BCMA CL

| EIVLTQSPGTLSLSPGERATLSCRASQSVSDEYLSWYQQKPGQAPRLIHSASTRATGIPDRFSGSGSGTDFTLAIIRLEPEDFAVYYCQQYGYPPDFTFGQGTKVEIK|RTVAAPSVFIFPPSDRKLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC|

Mab 22: Claim 9(i) SEQ ID NO: 48, 52, 53 and 54**SEQ ID NO: 48: anti-CD3 light chain with CrossMab**

- CD3 VH Region (SEQ ID NO: 7; CDRs of SEQ NOs: 1, 2 and 3)
- CD3 CL Region

| EVQLLESGGGLVQPGGSLRLSCAASGFTFS**TYAMN**WVRQAPGKGLEWVS**RIRSKYNNYATYYADSVKGR**FTISRDDSKNTLYLQMN
SLRAEDTAVYYCVR**HGNFGNSYVSWFAY**WGQGTLLTVSS| ASVAAPSVFIFPPSDEQLKSGTASVCLNNFYPREAKVQWKVDNALQ
SGNSQESVTEQDSKSTYLSSTLTLSKADYEKHKVYACEVTHQGLSPVTKSFNRGEC|

SEQ ID NO: 55: heavy chain long arm with CrossMab and charge variant mutations

- BCMA VH (SEQ ID NO: 10; CDRs of SEQ NOs: 21, 22 and 17)
- BCMA CH1 with Charge Variant Mutations
- CD3 VL (SEQ ID NO: 8; CDRs of SEQ NOs: 4, 5 and 6)
- CD3 CH1
- FC

| EVQLLESGGGLVQPGGSLRLSCAASGFTFS**DNAMG**WVRQAPGKGLEWVS**AI**SGPGS**STYYADSVKGR**FTISRDN**SKNTLYLQMN**SL
RAEDTAVYYCAK**VLGWFDY**WGQGTLLTVSS| ASTKGPSVFPLAPSSKSTSGGTAALGCLV**E**DYFPEPVTVSWNSGALTSGVHTFPAVLQ
SSGLYSLSVVTPSSSLGTQTYICNVNHKPSNTKVD**E**KVEPKSCD| **GGGGSGGGGS**| **QAVVTQEP**SLTVSPGGTVTL**CGSSTGAVTTS**
NYANWVQEKPGQAFRGLIG**GTNKR**APGTPARFSGSLGGAALTL**SGAQ**PEDEAEYY**CALWYSNLWV**FGGGT**KLTVLSS**| ASTKGPS
VFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSVVTPSSSLGTQTYICNVNHKPSNTKVDKKV
| EPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVV
SVLTVLHQDWLNGKEYKCKVSNKALGAPIEKISKAKGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYK
TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFCFSVMHEALHNHYTQKSLSLSPGK|

SEQ ID NO: 56: heavy chain short arm with charge variant mutations

- BCMA VH (SEQ ID NO: 10; CDRs of SEQ NOs: 21, 22 and 17)
- BCMA CH1 Charge Variant Mutations
- FC

| EVQLLESGGGLVQPGGSLRLSCAASGFTFS**DNAMG**WVRQAPGKGLEWVS**AI**SGPGS**STYYADSVKGR**FTISRDN**SKNTLYLQMN**SL
RAEDTAVYYCAK**VLGWFDY**WGQGTLLTVSS| ASTKGPSVFPLAPSSKSTSGGTAALGCLV**E**DYFPEPVTVSWNSGALTSGVHTFPAVLQ
SSGLYSLSVVTPSSSLGTQTYICNVNHKPSNTKVD**E**KV| EPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDV
SHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALGAPIEKISKAKGQPREPQVCTLPSPR
DELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFCFSVMHEALHNHYTQKSLSL
PGK|

SEQ ID NO: 54: anti-BCMA light chain

- BCMA VL (SEQ ID NO: 13; CDRs of SEQ NOs: 25, 26 and 20)
- BCMA CL

Annex A

Application No.: NC2018/0001149

Our Ref.: P48242CO-PCT

Your Ref.: P2018/000014

|EIVLTQSPGTLSPGERATLSCRASQSVSDEYLSWYQKPGQAPRLLIHSASTRATGIPDRFSGSGSGTDFTLAISRLEPED
FAVYYCQQYGYPDFTFGQGTKVEIK|RTVAAPSVFIFPPSDRKLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQE
SVTEQDSKDYSLSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC|